Oncology
Page 2 • 12 itemsGlobal oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Citius Oncology Ships First LYMPHIR International Order to Europe, Expanding Global Cancer Treatment Access
Citius Oncology ships first international LYMPHIR order to Europe through regional distribution partners, marking major milestone in global expansion.
Japanese Bridge Trial Requirements: Key PMDA Regulatory Updates 2024
Stay informed on the key PMDA regulatory updates for Japanese Bridge Trials in 2024, essential for drug XYZ's approval in cancer therapy.
NMPA Approval Trends ADCs: Novel Lung Cancer Therapies in China 2025
Discover the latest NMPA approval trends for antibody-drug conjugates (ADCs) targeting lung cancer in China, focusing on innovative therapies expected by 2025.
NMPA Conditional Approval Pathway: Accelerating Innovative Oncology Drug Access in China
The NMPA Conditional Approval Pathway is transforming access to innovative oncology drugs such as [Drug Name], expediting their availability for patients in China.
NMPA Approval ADCs Lung Cancer: Trends & Clinical Insights 2025
This article delves into the latest NMPA-approved antibody-drug conjugates (ADCs) for lung cancer, examining trends and clinical insights shaping 2025.
CAR-T Cell Therapy Japan: Regulatory Insights & Clinical Trial Landscape
This article delves into CAR-T cell therapy in Japan, highlighting regulatory frameworks and the evolving clinical trial landscape for hematologic malignancies.
CatalYm Doses First Patient in Phase 2/3 Trial of Visugromab for Cancer Cachexia
CatalYm begins Phase 2/3 VINCIT trial of visugromab, an anti-GDF-15 antibody targeting cancer cachexia in 518 patients with advanced cancers worldwide.
Fosun Health Wins Three Awards at GlobalHealth Asia-Pacific Forum 2026, Showcases China Solution Strategy
Fosun Health strengthened its regional presence at GlobalHealth Asia-Pacific Forum 2026, winning three major awards while showcasing its China Solution approach.
MorphoSys' MINJUVI (Tafasitamab) Approved in Australia for Relapsed/Refractory Follicular Lymphoma
Australia approves MINJUVI (tafasitamab) as first chemotherapy-free dual-targeted immunotherapy for relapsed/refractory follicular lymphoma patients.
Anixa Biosciences Lira-cel CAR-T Therapy Shows Positive Survival Data in Ovarian Cancer Phase 1 Trial
Anixa Biosciences announces positive survival data for Lira-cel CAR-T therapy in ovarian cancer Phase 1 trial, with presentation at ISCT 2026 meeting.
Hengrui Pharma Q1 2026 Results: Anti-PD-L1/TGF-βRII Fusion Protein Approved in China
Hengrui Pharma reports Q1 2026 growth with three innovative drug approvals including breakthrough anti-PD-L1/TGF-βRII bi-functional fusion protein in China.
Alphamab Oncology JSKN016 TROP2/HER3 Bispecific ADC Shows Promise for HER2-Negative Breast Cancer at ASCO 2026
Alphamab Oncology presents clinical data for JSKN016, a novel TROP2/HER3 bispecific ADC targeting HER2-negative breast cancer at ASCO 2026 conference.